Document Detail


FGFR1 amplification in squamous cell carcinoma of the lung.
MedLine Citation:
PMID:  23154548     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Amplification of fibroblast growth factor receptor 1 (FGFR1) has been reported in squamous cell lung carcinoma and may be a molecular target for therapy. Little is known, however, about the clinical and demographic correlates of FGFR1 amplification.
METHODS: The study is an Institutional Review Board approved retrospective analysis of 226 patients with squamous cell lung cancer seen at the Massachusetts General Hospital from 2005 to 2011. Clinical and demographic characteristics of all patients were obtained, as well as treatment details including surgery, radiation, and chemotherapy, and overall survival. fluorescence in situ hybridization was performed for FGFR1 on formalin-fixed paraffin-embedded tumor tissue. Clinical genotyping results were also reviewed where available.
RESULTS: Thirty-seven of 226 patients (16%) with squamous cell lung cancer were found positive for amplification using a definition of amplification of a gene to copy number control ratio of 2.2 or higher. FGFR1 amplification status was not associated with age, sex, stage, histologic subtype within squamous cell, smoking history, or pack-years of smoking. We found no significant difference in overall survival by FGFR1 amplification status as a whole; in the advanced stage subset, our findings are inconclusive because of the small sample size.
CONCLUSION: FGFR1 amplification was found in 16% of a clinical cohort of squamous cell lung cancer patients. The lack of any specific clinicodemographic features that correlates with FGFR1 amplification suggests that all squamous cell patients should be tested for this genomic change.
Authors:
Rebecca S Heist; Mari Mino-Kenudson; Lecia V Sequist; Swathi Tammireddy; Laura Morrissey; David C Christiani; Jeffrey A Engelman; A John Iafrate
Related Documents :
217528 - Primary oat cell carcinoma of the larynx: a case report and review of the literature.
2023448 - Surgical management of lung metastases. usefulness of resection with the neodymium:yttr...
23218588 - Mistletoe as complementary treatment in patients with advanced non-small-cell lung canc...
647178 - Sixth interim progress report of the british institute of radiology fractionation study...
20978768 - Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradia...
17908008 - Apparent spontaneous complete regression of a multifocal malignant mesothelioma of the ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer     Volume:  7     ISSN:  1556-1380     ISO Abbreviation:  J Thorac Oncol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-16     Completed Date:  2013-05-07     Revised Date:  2013-12-04    
Medline Journal Info:
Nlm Unique ID:  101274235     Medline TA:  J Thorac Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1775-80     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / genetics*,  mortality,  pathology
Adult
Aged
Aged, 80 and over
Carcinoma, Squamous Cell / genetics*,  mortality,  pathology
Female
Gene Amplification*
Humans
In Situ Hybridization, Fluorescence
Lung Neoplasms / genetics*,  mortality,  pathology
Male
Middle Aged
Neoplasm Staging
Prognosis
Receptor, Fibroblast Growth Factor, Type 1 / genetics*
Retrospective Studies
Survival Rate
Tumor Markers, Biological / genetics*
Grant Support
ID/Acronym/Agency:
P50 CA090578/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Tumor Markers, Biological; EC 2.7.10.1/FGFR1 protein, human; EC 2.7.10.1/Receptor, Fibroblast Growth Factor, Type 1
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The introduction of systematic genomic testing for patients with non-small-cell lung cancer.
Next Document:  Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Respon...